Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE: Infliximab for Small Bowel Crohn's Disease
NCT01181765Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2012
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Janssen Pharmaceutical. Primary endpoint: Endoscopic Improvement at Week 26. Started Jun 2012; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01181765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01181765.